Search

Rocket Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

2.48 2.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.38

Max

2.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

171M

123M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

202

EBITDA

179M

134M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+289.34% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-147M

250M

Ankstesnė atidarymo kaina

0.42

Ankstesnė uždarymo kaina

2.48

Rocket Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-30 19:53; UTC

Rocket Pharmaceuticals, Inc. shares fell sharply after pulling back from an early session high, remaining above its 20-day moving average.

2026-10-29 20:07; UTC

Rocket Pharmaceuticals, Inc. shares declined, pulling back from an earlier peak.

2026-10-28 22:21; UTC

Rocket Pharmaceuticals, Inc. shares are lower in after-market trading, reversing earlier gains to reach their lowest point of the day.

2026-10-27 20:01; UTC

Rocket Pharmaceuticals, Inc. shares are up sharply, showing strong momentum with a peak return exceeding 10% since Monday's close.

2026-10-26 20:07; UTC

Rocket Pharmaceuticals Inc shares are declining, having reached a session low earlier before recovering slightly, but remain below the 20-day moving average.

2026-10-23 20:07; UTC

Rocket Pharmaceuticals Inc shares are declining amid a broadly lower market, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

2026-10-22 20:07; UTC

Rocket Pharmaceuticals Inc shares are trading sharply higher, rebounding from a recent decline, as the broader market experiences significant upward movement.

2026-10-21 22:21; UTC

Rocket Pharmaceuticals Inc. advanced sharply in after-market trading, closing at its peak.

2026-10-20 20:21; UTC

Rocket Pharmaceuticals Inc gained sharply in after-market trading, rising since Tuesday's close.

2026-10-19 20:07; UTC

Correlated Moves

Rocket Pharmaceuticals shares are higher, supported by positive clinical trial results in the biotech sector, alongside gains in the SPDR S&P Biotech ETF.

2026-10-16 21:01; UTC

Rocket Pharmaceuticals Inc shares advanced in after-market hours on Friday.

2026-10-15 20:02; UTC

Rocket Pharmaceuticals Inc is trading sharply higher, reversing a recent trend of declines after closing lower in each of the previous four sessions.

2026-10-13 20:01; UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend amid broader market weakness, remaining well below their 20-day moving average.

2026-10-12 20:06; UTC

Rocket Pharmaceuticals Inc shares are declining, continuing a downward trend since Friday, finishing near session lows and significantly below its 20-day moving average.

2026-10-09 21:10; UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, showing a notable increase since Friday's close while remaining near the lower end of its one-month range.

2026-10-08 23:10; UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, moving up since Thursday's close despite pulling back from an earlier peak.

2026-10-07 20:07; UTC

Social Media
News

Rocket Pharmaceuticals' gene therapy candidate RP-A501 shows promising initial results; shares are higher since Tuesday, despite earlier intraday weakness.

2026-10-06 22:01; UTC

News

Rocket Pharmaceuticals secures a $150 million credit facility with Hercules Capital to bolster its financial position and support its Phase 2 study of RP-A501.

2026-10-05 20:06; UTC

Rocket Pharmaceuticals Inc is advancing amid a broader market recovery, despite experiencing a significant decline over the past month and remaining near its recent lows.

2026-10-02 19:45; UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Thursday and remaining significantly below its 20-day moving average.

2026-10-01 21:01; UTC

Rocket Pharmaceuticals Inc advanced in after-market trading on Thursday, recovering sharply from earlier losses amid broader market challenges.

2026-09-30 20:07; UTC

Rocket Pharmaceuticals Inc is gaining in today's trading session, advancing since Tuesday's close, despite a pullback from earlier session highs.

2026-09-29 23:01; UTC

Rocket Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close, despite a significant decline over the past month.

2026-09-28 23:26; UTC

Rocket Pharmaceuticals Inc gained in after-market hours on Monday, recovering from earlier losses, though it remains significantly lower compared to last month's close.

2026-09-25 23:56; UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

2026-09-24 20:01; UTC

Rocket Pharmaceuticals Inc shares fell sharply, reaching their lowest point of the day and remaining well below the 20-day moving average.

2026-09-23 23:46; UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

2026-09-22 23:21; UTC

Rocket Pharmaceuticals Inc is seeing a modest increase in after-market trading, building on Tuesday's close, although it remains below its 20-day moving average.

2026-09-21 22:06; UTC

Advanced modestly in after-market trading despite economic growth concerns.

2026-09-18 22:56; UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, maintaining an upward trend since Friday's close despite being below its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Rocket Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

289.34% į viršų

12 mėnesių prognozė

Vidutinis 9.5 USD  289.34%

Aukščiausias 15 USD

Žemiausias 4 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Rocket Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

7

Pirkti

4

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat